LIBERTY CORNER, N.J. — October 8, 2026
Lisata Therapeutics, Inc. announced that the U.S. Patent and Trademark Office (USPTO) has granted a new method-of-use patent for certepetide, its investigational cyclic peptide designed to improve the delivery of anticancer therapies into solid tumors. U.S. Patent No. 12,751,991, titled “Methods for Treating Pancreatic Cancer and Other Solid Tumors,” covers the use of certepetide in combination with at least one anticancer agent or therapy.
Patent Expands Intellectual Property Protection
The newly granted patent covers methods for treating, inhibiting, or reducing tumor volume in pancreatic cancer and other solid tumors, including metastatic, refractory, and drug-resistant cancers. According to Lisata, the patent is expected to strengthen intellectual property protection for certepetide, with the patent term extending to May 2041. The company also cited additional potential market exclusivity extending into November 2043.
Certepetide Targets Tumor Drug Delivery
Certepetide, formerly known as LSTA1, is an investigational internalizing RGD (iRGD) cyclic peptide designed to activate a tumor-specific uptake pathway. The approach aims to help co-administered or linked anticancer drugs penetrate and accumulate in solid tumors more effectively. Nonclinical research has also suggested that certepetide may modify the tumor microenvironment to improve tumor susceptibility to immunotherapies. Its clinical development includes investigation alongside standard-of-care chemotherapy for pancreatic cancer.
Advertisement
Lisata Advances Its Therapeutic Pipeline
Lisata Therapeutics is a clinical-stage pharmaceutical company developing therapies for serious diseases. The company’s portfolio includes certepetide for solid tumors, while its broader pipeline also includes MAR001, in Phase 2b development for severe hypertriglyceridemia, and MAR002 for acromegaly following the company’s acquisition of Marea Therapeutics. The new patent adds intellectual property protection for certepetide as its clinical development continues; the treatment remains investigational.
Source::Lisata Therapeutics,, press release
